Asset Planning Inc Makes New $40,000 Investment in Exact Sciences Co. (NASDAQ:EXAS)

Asset Planning Inc purchased a new position in Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 703 shares of the medical research company’s stock, valued at approximately $40,000.

A number of other hedge funds have also modified their holdings of EXAS. Thompson Investment Management Inc. boosted its position in shares of Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock worth $13,585,000 after acquiring an additional 36,505 shares during the last quarter. WCM Investment Management LLC boosted its position in shares of Exact Sciences by 1,153.2% during the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. boosted its position in shares of Exact Sciences by 67.5% during the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after acquiring an additional 11,800 shares during the last quarter. Zacks Investment Management purchased a new stake in Exact Sciences during the third quarter valued at $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Exact Sciences by 59.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after purchasing an additional 125,192 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Trading Down 2.5 %

NASDAQ EXAS opened at $49.31 on Friday. The company’s 50-day moving average price is $56.15 and its 200-day moving average price is $60.09. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The stock has a market cap of $9.13 billion, a PE ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of recent research reports. Piper Sandler decreased their price target on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Barclays initiated coverage on shares of Exact Sciences in a research note on Thursday, January 23rd. They set an “overweight” rating and a $70.00 price target on the stock. BTIG Research upped their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Evercore ISI decreased their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Robert W. Baird reduced their target price on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.